Breakthrough <scp>SARS</scp> – <scp>CoV</scp> ‐2 Infections in Patients With <scp>Immune‐Mediated</scp> Disease Undergoing B Cell–Depleting Therapy: A Retrospective Cohort Analysis

Abstract

IMID patients receiving BCDT regardless of vaccine status appear to be vulnerable to infection with SARS-CoV-2, and use of BCDT is frequently associated with severe outcomes. Outpatient use of anti-SARS-CoV-2 monoclonal antibody therapy appears to be associated with enhanced clinical outcomes.